SCHEMBL845641

SCHEMBL845641

COc1cccc(C(=O)N2CCC[C@H]2C(=O)Nc2ccc(/C=C/c3ccc(NC(=O)[C@@H]4CCCN4C(=O)c4cccc(OC)c4OC)cc3)cc2)c1OC

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.53
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
ALDH1A1 P00352 2/20 0.48
HTT P42858 1/20 0.48
ROCK2 O75116 1/20 0.46
TDP1 Q9NUW8 2/20 0.46
TP53 P04637 1/20 0.46
LMNA P02545 1/20 0.46
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
EP300 Q09472 2/20 0.46
CREBBP Q92793 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13272181 1.00 MAPK1 (0.53) MAPK1CYP2C9CYP2C19ALDH1A1HTT
SCHEMBL10119619 0.91 MAPK1 (0.46) MAPK1CYP2C9CYP2C19ALDH1A1HTT
SCHEMBL845284 0.91 MAPK1 (0.58) MAPK1CYP2C9CYP2C19ALDH1A1HTT
SCHEMBL845290 0.84 HCRTR1 (0.52) MAPK1CYP2C9CYP2C19ALDH1A1HTT
SCHEMBL845643 0.83 MAPK1 (0.50) MAPK1CYP2C9CYP2C19ALDH1A1HTT
SCHEMBL874313 0.83 MAPK1 (0.50) MAPK1CYP2C9CYP2C19ALDH1A1HTT
SCHEMBL845312 0.82 GAA (0.60) MAPK1CYP2C9CYP2C19ALDH1A1HTT
SCHEMBL845002 0.82 CYP2C9 (0.55) MAPK1CYP2C9CYP2C19ALDH1A1HTT
SCHEMBL845008 0.82 ALDH1A1 (0.54) MAPK1CYP2C9CYP2C19ALDH1A1HTT
SCHEMBL845021 0.82 ALDH1A1 (0.53) MAPK1CYP2C9CYP2C19ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143288-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-27 US disclosed
US-8143288-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-27 US disclosed
EP-1893573-B1 INHIBITORS OF HCV REPLICATION BRISTOL MYERS SQUIBB CO (US) 2010-07-21 EP disclosed